Clinical Trial Update: Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 study of TC-5619 in adults with attention-deficit/hyperactivity disorder evaluates efficacy, safety, and tolerability. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• TC-5619

Snippet

Sponsor: Targacept Inc. | Conditions: ADHD | Phase 2 | Status: COMPLETED